- Home
- IMPP vs TARA Comparison
IMPP vs TARA Comparison
Compare IMPP & TARA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IMPP | TARA |
|---|---|---|
| Founded | 1981 | N/A |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 234.7M | 236.1M |
| IPO Year | 2021 | 2014 |
Fundamental Metrics
Financial Performance| Metric | IMPP | TARA |
|---|---|---|
| Price | $5.31 | $3.94 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | N/A | ★ $24.40 |
| AVG Volume (30 Days) | ★ 358.1K | 352.1K |
| Earning Date | 05-22-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 38.25 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,948,000.00 |
| Revenue This Year | $51.79 | N/A |
| Revenue Next Year | $6.97 | N/A |
| P/E Ratio | $3.68 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.15 | $3.02 |
| 52 Week High | $6.57 | $7.82 |
Technical Indicators
Market Signals| Indicator | IMPP | TARA |
|---|---|---|
| Relative Strength Index (RSI) | 59.91 | 49.66 |
| Support Level | $4.64 | $3.73 |
| Resistance Level | $5.30 | $4.17 |
| Average True Range (ATR) | 0.22 | 0.15 |
| MACD | 0.04 | 0.00 |
| Stochastic Oscillator | 76.67 | 60.00 |
Price Performance
Historical ComparisonAbout IMPP Imperial Petroleum Inc.
Imperial Petroleum Inc is a provider of international seaborne transportation services to oil producers, refineries, and commodities traders. It owns and operates a fleet of six medium-range product tankers that carry refined petroleum products such as gasoline, diesel, fuel oil, and jet fuel, as well as edible oils and chemicals.
About TARA Protara Therapeutics Inc.
Protara Therapeutics Inc is a clinical-stage biopharmaceutical company focused on advancing its therapies for the treatment of cancer and rare diseases. Its drug development pipeline includes: TARA-002, an investigational cell therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs); and IV Choline Chloride, an investigational phospholipid substrate replacement therapy, for patients receiving parenteral support, or PS, which includes both nutrition and fluids.